重组人脑利钠肽与厄贝沙坦联合用药方案治疗慢性充血性心力衰竭的临床评价

Clinical Evaluation of Recombinant Human Brain Natriuretic Peptide Combined with Irbesartan in the Treatment of Chronic Congestive Heart Failure

目的分析重组人脑利钠肽与厄贝沙坦联合用药方案治疗慢性充血性心力衰竭的临床疗效,为临床合理用药提供参考。方法抽取治疗的90例慢性充血性心力衰竭患者(2013年10月~2015年12月)作为实验的目标对象,对90例慢性充血性心力衰竭患者实施计算机随机分组(常规组和实验组)。常规组45例患者实施常规治疗,实验组45例患者在常规治疗的基础上实施重组人脑利钠肽与厄贝沙坦联合治疗,分析比较两组患者治疗前后的心功能改善情况、心率、血压、左心室射血分数、左心室舒张末期内径及不良反应发生率。结果常规组45例患者和实验组45例患者的总有效率分别为77.78%、93.33%,组间存在显著差异,P<0.05;两组患者比较可得,组间治疗前的心率、血压、左心室射血分数、左心室舒张末期内径的结果无显著差异,P>0.05;但组间治疗后的心率、血压、左心室射血分数、左心室舒张末期内径的结果存在差异,P<0.05;常规组45例患者的不良反应发生率和实验组45例患者无显著区别,P>0.05。结论重组人脑利钠肽与厄贝沙坦联合治疗慢性充血性心力衰竭具有显著的临床疗效,且毒副作用较小。

Objective To explore the clinical efficacy of recombinant human brain natriuretic peptide and irbesartan combination regimen in the treatment of chronic congestive heart failure（ CCHF）,and to provide reference for clinical rational drug use. Methods During the period from October 2013 to December 2015,a total of 90 cases with CCHF were treated in Center Hospital of Liaoyang. These patients were randomly divided into two groups： the conventional group and the experimental group,45 cases in each group; the conventional group received routine treatment,and the experimental group was treated with recombinant human brain natriuretic peptide combined with irbesartan,based on the routine treatment. heart function improvement,heart rate,blood pressure,left ventricular ejection fraction,left ventricular end diastolic diameter and adverse reaction rate before and after the treatment were compared between two groups. Results In the conventional group and in the experimental group,the total effective rate was 77. 78% and93. 33% respectively,there were significant differences between groups（ P〈0. 05）. heart rate,blood pressure,left ventricular ejection fraction,left ventricular diastolic end diastolic diameter before treatment had no significant difference between groups（ P〉0. 05）; but there were differences in these indexes after treatment between groups（ P〈0. 05）,there was no significant difference in the incidence of adverse reactions between the two groups（ P〉0. 05）.Conclusions The clinical efficacy of recombinant human brain natriuretic peptide and irbesartan combination regimen in the treatment of chronic congestive heart failure is remarkable,and with less toxic and side effects.